Delivery Order SPE2DB24D2105-SPE2DB25FAQBV
- Not listed
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 25, 2025, for IMBRUVICA 140 MG tablets in a quantity of 28 units. This is a firm fixed-price, non-set-aside contract with a ceiling value of $7,575.75 and an ultimate completion date of September 16, 2025. The delivery order is being performed at the company's corporate office location in Conshohocken, PA. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) valued at $53,030.25 with a firm fixed price structure. The order is scheduled for completion by September 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract and is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count packaging) under a firm fixed price contract type. The delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, carries no set-aside designation, indicating it was awarded through open competition. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Imbruvica 420 mg tablets (28-count packaging) with a contract value of $7,575.75 and completion date of September 26, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX. The...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a $8,116.87 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on September 19, 2025, for the supply of Imbruvica 140 mg capsules (90-count units). This non-set-aside, competitively awarded delivery order is scheduled for completion by October 10, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) with delivery to Conshohocken, Pennsylvania. This contract, awarded on August 4, 2025, utilizes a firm fixed-price structure with an ultimate completion date of August 25, 2025. The award was made without a set-aside designation, indicating it was competitively awarded among qualified vendors. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $15,151.52 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count units) on September 8, 2025, with an ultimate completion date of September 29, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award status. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Imbruvica 420 mg tablets (28-count packaging) with a contract ceiling value of $15,151.52. This is a firm fixed-price delivery order with an ultimate completion date of October 7, 2025, representing a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The award was competitively awarded with no set-aside designation, and performance...
- The Defense Logistics Agency awarded a $7,575.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 70 mg capsules (28-count packaging) with a completion date of June 24, 2025. This non-set-aside, competitively awarded contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQBVDelivery Order
The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor headquartered in Conshohocken, Pennsylvania. The company maintains an extensive portfolio of competitively awarded contracts with the Defense Logistics Agency and its Medical Supply Chain, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. All reviewed contract awards were non-set-aside and firm fixed price arrangements, demonstrating the company's capability to meet federal procurement requirements through open competition and serve customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/18/25 |